M184I/V及E138K/M184I/V双突变对EFdA抗病毒活性的影响
本研究通过定点诱变构建含M184I/V和/或E138K突变的HIV重组病毒,在组织培养中评估其对EFdA等核苷类化合物的敏感性。结果显示,含M184I/V及E138K双突变的病毒仍保留对EFdA的敏感性,且EFdA选择压力下未产生E138K突变,提示EFdA对携带这些突变的病毒仍有活性。
要点
- EFdA对含M184I/V突变的HIV仍保留显著活性。
- M184I/V与E138K双突变不降低EFdA的抗病毒活性。
- EFdA选择压力下未筛选出E138K补偿突变。
核心结论
- EFdA对含M184I/V及E138K双突变的HIV病毒仍保持抗病毒活性。
研究设计与样本
- 通过定点诱变构建含M184I/V和/或E138K突变的HIV重组病毒,在组织培养中评估药物敏感性。
主要发现
- 含M184I/V及E138K双突变的病毒对EFdA的敏感性得以保留。
- 在EFdA选择压力下未产生E138K突变。
临床怎么用
- EFdA可能对携带M184I/V及E138K突变的HIV病毒仍有疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a potent nucleoside analogue inhibitor of HIV that has an unusually long half-life. Cell culture selections with either EFdA or lamivudine using both subtype B and non-B clinical isolates selected the M184I/V substitutions in reverse transcriptase (RT). Unlike lamivudine, however, EFdA retained significant activity against viruses containing the M184I/V substitutions. In other clinical trials that evaluated rilpivirine together with emtricitabine in first-line therapy, the emergence of both the M184I/V and E138K mutations in RT was demonstrated. Moreover, the M184I/V and E138K substitutions were shown to be compensatory for each other with regard to both efficiency of RT activity and viral replicative capacity. This creates concern that E138K might emerge as a compensatory mutation for M184I/V in the aftermath of the use of EFdA. OBJECTIVES: We wished to determine whether the E138K mutation in HIV RT together with M184I/V would compromise the activity of EFdA. METHODS: Recombinant viruses containing the M184I/V and/or E138K substitutions were generated by site-directed mutagenesis and evaluated in tissue culture for susceptibility to various nucleoside compounds, including EFdA. RESULTS: Susceptibility to EFdA was retained in M184I/V viruses that also contained the E138K substitution. Moreover, the E138K substitution was not generated in these studies under selection pressure with EFdA. CONCLUSIONS: These findings help to alleviate concern that EFdA may not be active against viruses that contain both the M184I/V and E138K substitutions in RT.
引用
- Oliveira M, Brenner BG, Xu H, et al. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA. J Antimicrob Chemother. 2017. PMID: 28961903. doi:10.1093/jac/dkx280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。